EPS for Ovid Therapeutics Inc. (OVID) Expected At $-0.42; 1 Bullish Analysts Covering THL Credit, Inc. (TCRD)

March 14, 2018 - By Kurt Siggers

Analysts expect Ovid Therapeutics Inc. (NASDAQ:OVID) to report $-0.42 EPS on March, 15.After having $-0.38 EPS previously, Ovid Therapeutics Inc.’s analysts see 10.53% EPS growth. The stock decreased 0.60% or $0.05 during the last trading session, reaching $8.28. About 75,733 shares traded. Ovid Therapeutics Inc. (NASDAQ:OVID) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 8 analysts covering THL Credit (NASDAQ:TCRD), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. THL Credit had 26 analyst reports since August 7, 2015 according to SRatingsIntel. As per Friday, August 7, the company rating was maintained by National Securities. Deutsche Bank maintained the stock with “Hold” rating in Thursday, March 8 report. On Friday, August 12 the stock rating was maintained by Citigroup with “Neutral”. Jefferies maintained THL Credit, Inc. (NASDAQ:TCRD) rating on Tuesday, August 15. Jefferies has “Hold” rating and $10.0 target. The firm has “Hold” rating given on Tuesday, August 8 by Deutsche Bank. Keefe Bruyette & Woods upgraded the stock to “Outperform” rating in Friday, February 19 report. As per Saturday, September 5, the company rating was upgraded by TheStreet. The firm earned “Market Perform” rating on Friday, August 5 by Wells Fargo. The firm has “Outperform” rating by Wells Fargo given on Monday, April 4. The firm has “Hold” rating by Keefe Bruyette & Woods given on Wednesday, March 7. See THL Credit, Inc. (NASDAQ:TCRD) latest ratings:

07/03/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $9.0 Maintain
07/03/2018 Broker: Jefferies Rating: Hold New Target: $9.0 Maintain
08/03/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $10 New Target: $9.5 Maintain
08/03/2018 Broker: Maxim Group Old Rating: Buy New Rating: Hold Downgrade
10/11/2017 Broker: Maxim Group Rating: Buy New Target: $11.5 Maintain
03/11/2017 Broker: Jefferies Rating: Hold New Target: $10.0 Maintain
16/10/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $10.5 Maintain
22/09/2017 Broker: Jefferies Rating: Hold New Target: $10.0 Maintain
15/09/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $10.5 Maintain

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company has market cap of $203.72 million. The firm is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome. It currently has negative earnings. It is also developing OV935, a drug candidate that is in Phase I trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the hospital setting.

Investors sentiment increased to 0.97 in 2017 Q3. Its up 0.01, from 0.96 in 2017Q2. It is positive, as 6 investors sold THL Credit, Inc. shares while 22 reduced holdings. 10 funds opened positions while 17 raised stakes. 11.74 million shares or 4.50% less from 12.29 million shares in 2017Q2 were reported. Goldman Sachs Gru owns 69,124 shares for 0% of their portfolio. 356,642 were reported by Buckhead Capital Ltd Liability Co. Athena Advsrs Limited Liability Co reported 109,774 shares stake. Geode Lc reported 71,181 shares. Group Inc One Trading L P stated it has 0% of its portfolio in THL Credit, Inc. (NASDAQ:TCRD). Private Advisor Gp Ltd Llc invested in 50,651 shares or 0.01% of the stock. Howe And Rusling holds 520 shares or 0% of its portfolio. Jpmorgan Chase & has 5,144 shares. Tradewinds Cap Lc, Washington-based fund reported 500 shares. Cs Mckee L P owns 100,000 shares. Guggenheim Capital Limited Liability Company reported 282,007 shares. Highlander Cap Management Lc has invested 0.43% in THL Credit, Inc. (NASDAQ:TCRD). Ballentine Prtn Ltd Liability stated it has 0.02% of its portfolio in THL Credit, Inc. (NASDAQ:TCRD). Baystate Wealth Limited Liability has 500 shares. Planning holds 10,250 shares.

Since March 9, 2018, it had 1 buy, and 1 sale for $309,319 activity. 1 THL Credit, Inc. (NASDAQ:TCRD) shares with value of $8 were bought by Rusnak-Carlson Sabrina. Another trade for 37,339 shares valued at $309,327 was made by Tillinghast Sam W. on Friday, March 9.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.